Company aims for technology advancement and platform expansion with Korea's first influenza vaccine using an adjuvant Interim ...

ICON plc, (NASDAQ: ICLR) a world-leading healthcare intelligence and clinical research organisation, has been rated as one of the top-performing contract research organisations (CRO) for phase 1 clini ...

NanoViricides, Inc., a publicly traded company (NYSE Amer.:NNVC) (the “Company”), and a clinical stage, leading global pioneer in the development of broad-spectrum antivirals based on host-mimetic ...

Phase-III trial of indigenous one-shot dengue vaccine by Panacea Biotec shows promising results in India, aiming for ...

AIIMS is testing a new Indian-adapted Mediterranean diet to help heart disease patients. The trial results are set to provide ...

MSD unveiled the launch of the Phase III trials of MK-8527 at the International AIDS Society (IAS) 2025 conference.

Enrolment of about 10,500 participants in the phase III clinical trial of the indigenous one-shot Panacea Biotec developed dengue vaccine, DengiAll, is likely to be completed by October across 20 ...

Enrolment of about 10,500 participants in the phase III clinical trial of the indigenous one-shot Panacea Biotec developed ...

Rahway, New Jersey Wednesday, July 16, 2025, 17:30 Hrs [IST] ...

FDA Protocol Review Completed ~~ Rho, Inc. Selected as Clinical Research Partner ~ SAN DIEGO, CA / ACCESS Newswire / July 16, 2025 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company" ...

A recent study found that only 15% of cancer survivors discussed trials with their healthcare providers, with ...